Latest Headlines

Latest Headlines

Therapeutic cancer vaccines: Optimism for the future at BIO 2012

Glenn Dranoff of the Cancer Vaccine Center at Dana-Farber Cancer Institute opened "Therapeutic Cancer Vaccines: Renewed Optimism for the Product Pipeline" at BIO 2012 with a positive note: "It's an exciting time for immunotherapy."

Gotham's genome center grabs grant for bioinformatics hires

The New York Genome Center has won a grant to fuel its ambitious plans to establish one of the country's leading genomics institutes in Manhattan.

$110M therapeutics center on tap for UC San Diego campus

UC San Diego officials have unveiled ambitious plans to erect a sparkling new facility to house life sciences startups and academics focused on cancer research.

4s3 Bioscience gains a Pritzker's drug delivery development dough

4s3 Bioscience in Medford, MA, recently raised $20 million in Series A financing to fuel its drug delivery technology to treat muscle disorders. As Xconomy reports, the cash comes from KLP Enterprises; Karen Pritzker, of the Hyatt hotel chain Pritzker family, formed the trust.

In turnabout, India to send inspectors overseas

India is looking for drug plant inspectors. It wants to reach its full planned complement of 1,364--864 of which are currently on the job--and begin inspecting foreign plants. But even that's not

Aileron scores $1.1B development pact with Roche

Aileron Therapeutics' stapled peptide platform has won over Roche, which is paying $25 million upfront and up to $1.1 billion more in milestones to explore the potential to deliver a new generation

Northstar burns out

Seattle-based Northstar Neuroscience is opting to liquidate its assets, terminating all but a skeleton staff to handle the dissolution of the company. Northstar's stock plunged in early 2007 after

Novartis presents promising lung disease data

Novartis presented positive mid-stage data for NVA237, a lung disease treatment, at the annual European Respiratory Society (ERS) show in Berlin, Germany. Novartis licensed the drug for from Sosei

Side effects force Neurogen to suspend dosing

Neurogen has suspended dosing in a Phase II/III trial of its insomnia drug adipiplon after registering next day side effects. Researchers had been dosing patients with various amounts of immediate

Australia approves a new bird flu vaccine

Australian officials have approved a bid flu vaccine developed by CSL. And the government announced a $160 million budget to stockpile additional vaccines to help protect the country from an
  • 1
  • 2
  • next ›
  • last »